Country: Canada
Language: English
Source: Health Canada
MAGNESIUM CHLORIDE; SODIUM CHLORIDE; LACTIC ACID; SODIUM BICARBONATE
BAXTER CORPORATION
B05ZA
HEMODIALYTICS, CONCENTRATES
0.108G; 6.449G; 0.284G; 58.8G
SOLUTION
MAGNESIUM CHLORIDE 0.108G; SODIUM CHLORIDE 6.449G; LACTIC ACID 0.284G; SODIUM BICARBONATE 58.8G
INTRAVENOUS
5000ML
Ethical
HEMODIALYSIS SOLUTION
Active ingredient group (AIG) number: 0451567002; AHFS:
APPROVED
2014-12-31
_ _ _Prism0CAL _ _Page 1 of 22_ PRESCRIBING INFORMATION PRISM0CAL Lactic acid 0.284 g/L, Magnesium chloride hexahydrate 0.108 g/L, Sodium bicarbonate 58.8 g/L, and Sodium chloride 6.449 g/L solution. Sterile solution for hemofiltration and hemodialysis Hemodialytics, concentrates, ATC code: B05Z A BAXTER CORPORATION MISSISSAUGA, ON CANADA, L5N 0C2 Date of Initial Approval: December 24, 2005 Date of Revision: March 20, 2019 Submission Control No: 218872 Baxter and Prism0CAL are trademarks of Baxter International Inc., or its subsidiaries. _ _ _Prism0CAL _ _Page 2 of 22_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................6 DRUG INTERACTIONS ....................................................................................................7 DOSAGE AND ADMINISTRATION ................................................................................8 OVERDOSAGE ................................................................................................................11 ACTION AND CLINICAL PHARMACOLOGY ............................................................12 STORAGE AND STABILITY ..........................................................................................12 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................13 PART II: SCIENTIFIC INFORMATION ...............................................................................15 PHARMACEUTICAL INFORMATION . Read the complete document